Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Biochemistry & Molecular Biology
Yu Gao et al.
Summary: This study found that SARS-CoV-2 spike-specific CD4(+) and CD8(+) T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against the Omicron variant. Additionally, T cells induced by BNT162b2 vaccination exhibit higher cross-reactivity to the Omicron variant compared to T cells induced by prior SARS-CoV-2 infection.
Letter
Medicine, General & Internal
Fabian Schmidt et al.
Summary: Neutralization assays showed much lower omicron neutralization compared to Wuhan-hu-1 after two doses of mRNA vaccine, but individuals who received a booster vaccine or were vaccinated after recovering from Covid-19 exhibited high levels of omicron neutralization.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Surgery
Deepali Kumar et al.
Summary: The Omicron variant of the SARS-CoV-2 virus has become the dominant circulating strain globally, and three doses of mRNA COVID-19 vaccine are recommended for transplant recipients. However, there is limited research on the immunogenicity of mRNA vaccines specifically against the Omicron variant. This study analyzed the neutralization effects of Omicron in transplant recipients who received three doses of mRNA-1273 vaccine, and the results showed poor neutralizing responses against the Omicron variant in these patients.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Multidisciplinary Sciences
Roanne Keeton et al.
Summary: Despite reduced neutralizing antibody activity, T cell responses induced by vaccination or infection can cross-recognize the Omicron variant and provide protection.
Letter
Medicine, General & Internal
Jingyou Yu et al.
Summary: Although immunity from two doses of BNT162b2 vaccine diminishes over time, a booster dose significantly enhances the neutralizing antibodies against both the BA.1 and BA.2 variants.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Aekkachai Tuekprakhon et al.
Summary: The Omicron variant of SARS-CoV-2 has rapidly spread globally and has evolved into different sublineages, with BA.4 and BA.5 dominating in South Africa. These sublineages show reduced neutralization by vaccine and naturally immune serum, indicating the possibility of repeat Omicron infections.
Letter
Virology
Hu Li et al.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Multidisciplinary Sciences
Qian Wang et al.
Summary: SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have become dominant in the United States and South Africa, raising concerns about their ability to evade neutralizing antibodies and compromise the efficacy of COVID-19 vaccines and therapeutic monoclonals. A systematic antigenic analysis reveals that BA.2.12.1 and BA.4/5 have different levels of resistance to antibodies, with BA.2.12.1 being modestly resistant and BA.4/5 being substantially resistant. Certain mutations in the spike protein facilitate antibody escape, but compromise the spike affinity for the viral receptor. Only bebtelovimab retains full potency against both subvariants.
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: Omicron sublineages BA.2.12.1, BA.4 and BA.5 have higher transmissibility and increased evasion of neutralizing antibodies compared to the BA.2 lineage. They exhibit similar binding affinities to the ACE2 receptor as BA.2. BA.1 infection after vaccination boosts humoral immune memory against wild-type SARS-CoV-2, but these antibodies are largely evaded by BA.2 and BA.4/BA.5 variants.
Article
Biochemistry & Molecular Biology
Houriiyah Tegally et al.
Summary: The genomic characterization of the SARS-CoV-2 Omicron lineages BA.4 and BA.5, responsible for the fifth wave of the COVID-19 pandemic in South Africa, reveals their continued viral diversification and sheds light on the potential mechanisms that allow these new lineages to outcompete their predecessors. These new lineages, BA.4 and BA.5, share identical spike proteins with BA.2 but have certain differences such as the presence of the 69-70 deletion, L452R, F486V, and the wild-type amino acid at Q493. They can be identified by the S-gene target failure, a proxy marker associated with the 69-70 deletion. BA.4 and BA.5 have rapidly replaced BA.2 and have become the dominant lineages in South Africa.
Letter
Medicine, General & Internal
Nicole P. Hachmann et al.
Summary: A small study found that omicron subvariants BA.2.12.1, BA.4, and BA.5 of SARS-CoV-2 were more likely to evade neutralizing antibodies induced by both vaccination and previous infection compared to the prior omicron subvariants BA.1 and BA.2.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Victor H. Ferreira et al.
Summary: Transplant recipients who are partially or fully vaccinated after infection with Omicron BA.1 have the strongest immune response, including high levels of neutralizing antibodies and polyfunctional T-cell responses. These patients also show cross-neutralization against BA.2. Immunocompromised individuals are at risk for severe COVID-19, and these findings have implications for understanding the risk of infection, reinfection, and disease severity in this population.
NATURE COMMUNICATIONS
(2022)
Letter
Immunology
Kyemyung Park et al.
Article
Multidisciplinary Sciences
Marie-Ming Aynaud et al.
Summary: The study introduces a platform called C19-SPAR-Seq, which can analyze tens of thousands of patient samples for SARS-CoV-2 in a single run, with high specificity and sensitivity demonstrated through experimental trials in clinical diagnostics.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Immunology
Marcus R. Pereira et al.
Summary: The study found that solid organ transplant recipients hospitalized with COVID-19 had similar overall outcomes as non-transplant patients, suggesting that chronic immunosuppression may not be an independent risk factor for poor outcomes in COVID-19.
TRANSPLANT INFECTIOUS DISEASE
(2021)
Letter
Medicine, General & Internal
William A. Werbel et al.
ANNALS OF INTERNAL MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Lawrence Corey et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Kizzmekia S. Corbett et al.
Summary: In nonhuman primates (NHPs), vaccination with mRNA-1273 induces dose-dependent antibody responses, leading to a significant reduction in viral replication post SARS-CoV-2 challenge. Replication of the virus correlates strongly with antibody levels and neutralizing activity, with lower levels required in the lower airway than in the upper airway. Passive transfer of mRNA-1273-induced IgG is sufficient to provide protection, indicating that humoral immune responses induced by mRNA-1273 vaccine are effective against SARS-CoV-2 in NHPs.
Article
Immunology
Tina Marinelli et al.
Summary: This study illustrates the range of COVID-19 illness in transplant patients, identifying risk factors for severe disease. The majority of patients developed antibodies by two weeks, with varying stability over time. Prolonged viral shedding was observed in a minority of patients.
Article
Medicine, Research & Experimental
Kento T. Abe et al.
